ADPT News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

AD

Mkt Cap

$3.84B

Volume

1.63M

Next Earnings

November 4th

Loading chart

AD

ADPTAdaptive Biotechnologies Corporation Common Stock

ADPT

Pay with—

Available Balance0.00

AD

Mkt Cap

$4.08B

Volume

1.63M

Next Earnings

November 4th

Chart Financials Earnings News About Insider Filings

An Adaptive Biotechnologies Insider Sold $8.5 Million in Stock After an 85% RunHarlan Robins, chief scientific officer of Adaptive Biotechnologies, sold 386,240 shares worth $8.5 million on July 2, 2026, under a pre-scheduled Rule 10b5-1 trading plan established in March. Despite the sale, Robins retained over 1 million shares valued at $21.6 million. The transaction appears to be a diversification move rather than a sign of concern, as the company's MRD diagnostics business is accelerating with 35% revenue growth and narrowing losses.The Motley Fool · Jul 12, 2026

Adaptive Biotechnologies Business Separation May Unlock Greater ValueAdaptive Biotechnologies announced plans to separate its Minimal Residual Disease (MRD) and Immune Medicine businesses. William Blair analyst Andrew Brackmann believes the separation could simplify the investment story and create strategic flexibility for the MRD franchise. The Immune Medicine segment is expected to contribute little to valuation and carries $15-20 million in annual cash burn. The company also priced a $300 million convertible senior notes offering to repay debt and fund MRD initiatives.Benzinga · Jun 17, 2026

Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes OfferingAdaptive Biotechnologies priced a $300 million offering of 0% convertible senior notes due 2031 (expandable to $345 million with greenshoe option). The company plans to use proceeds to repay its OrbiMed Purchase Agreement, fund capped call transactions at a 100% premium, repurchase $25 million in common stock, and support general corporate purposes and MRD business initiatives. The notes have an initial conversion price of $24.11 per share, representing a 40% premium to the June 16, 2026 closing price of $17.22.GlobeNewswire Inc. · Jun 17, 2026

Adaptive Biotechnologies Stock Rises On Plan To Split MRD, Immune Medicine BusinessesAdaptive Biotechnologies announced plans to separate its Minimal Residual Disease (MRD) and Immune Medicine businesses to unlock shareholder value. The MRD segment has shown strong growth, increasing revenue from $103 million in 2023 to $212 million in 2025, while the Immune Medicine segment has advanced in drug discovery capabilities. The company expects to finalize its separation strategy by end of 2026. ADPT shares rose 0.74% to $17.59, with analysts maintaining a Buy rating and average price target of $20.20.Benzinga · Jun 16, 2026

Stock Market Today: S&P 500, Nasdaq Futures Fall, Dow Gains Amid US-Iran Deal— SpaceX, Dave And Buster's, Western Digital In Focus (UPDATED)U.S. stock futures showed mixed performance on Tuesday following a preliminary U.S.-Iran agreement. The Dow Jones and Nasdaq 100 advanced while the S&P 500 fell slightly. Key movers included SpaceX surging with a market cap nearing $3 trillion, Dave and Buster's dropping 11.44% on weak earnings, Western Digital gaining 4.97% on analyst upgrade, and Paranovus Entertainment surging 30.07% on a direct offering announcement.Benzinga · Jun 16, 2026

What Does an Adaptive Biotech Insider's Sale of Nearly 40,000 Shares Mean for Investors?Adaptive Biotechnologies' Chief People Officer Francis Lo sold 39,741 shares worth approximately $695,000 on June 4, 2026. The sale was part of a pre-arranged trading plan and involved exercising stock options. Despite the sale, Lo maintains substantial holdings of 250,934 direct shares and 483,489 stock options, indicating continued confidence in the company. The transaction is considered routine and not a red flag for investors.The Motley Fool · Jun 14, 2026

Harvest Investment Services Dumps 356,000 Adaptive Biotechnologies (ADPT) Shares Worth $5.7 MillionHarvest Investment Services completely exited its position in Adaptive Biotechnologies, selling 356,114 shares worth approximately $5.67 million during Q1 2026. The sale was part of a broader portfolio restructuring where the firm closed 48 positions. Despite the exit, ADPT shares have appreciated 57.78% over the prior year, with strong Q1 growth in cancer diagnostic testing.The Motley Fool · May 26, 2026

Adaptive Biotechnologies' Chief Operating Officer Sold Over 19,000 Company Shares. Here's What That Means for Investors.Adaptive Biotechnologies' COO Julie Rubinstein sold 19,037 shares worth approximately $271,000 on April 27, 2026, as part of a pre-established Rule 10b5-1 trading plan. The sale represented only 4.8% of her holdings, and she maintains significant equity stakes with 377,802 directly-held shares and 45,731 options. The transaction is not considered a red flag, as the company reported strong 55% revenue growth in 2025 while significantly reducing operating losses.The Motley Fool · May 4, 2026

Should You Sell Adaptive Biotechnologies (ADPT) After Its President and COO Sold 57,000 Shares?Adaptive Biotechnologies' President and COO Julie Rubinstein sold 57,180 shares (~$826,000) between April 14-16, 2026, through the exercise and immediate sale of stock options. The analyst characterizes this as a liquidity event rather than a loss of confidence, noting Rubinstein retains 408,160 shares and 148,770 options. The company's MRD cancer monitoring revenue grew 46% last year, with expanded Medicare coverage supporting future growth.The Motley Fool · Apr 18, 2026

Adaptive Biotech Insider Sells $554K as Revenue Jumps 55%, but Here's What Investors Should Focus OnAdaptive Biotechnologies' President and COO Julie Rubinstein sold 38,120 shares worth approximately $554,000 through a pre-arranged trading plan. Despite the insider sale, the company reported strong fundamentals with 55% year-over-year revenue growth to $277 million, driven by its MRD segment which now represents over 75% of sales. Net losses narrowed significantly from $159.6 million to $59.5 million, and the MRD segment achieved positive adjusted EBITDA. The article emphasizes that the sale appears compensation-driven rather than a bearish signal, with the real focus being on whether the company can sustain profitability growth.The Motley Fool · Apr 8, 2026

to start trading

AD

ADPTAdaptive Biotechnologies Corporation Common Stock

ADPT

Pay with—

Available Balance0.00

Your PositionYou don't own any ADPT yet.

Related Tickers

Earnings